AI Article Synopsis
- A new series of cyclic benzamidines was created and demonstrated selectivity for blocking the NR2B subtype of NMDA receptors.
- Compound 29 from this series was tested and found to be effective when taken orally in a rat model that simulates pain caused by carrageenan.
- This research suggests potential for developing pain relief treatments targeting specific NMDA receptor subtypes.
Article Abstract
A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2007.04.084 | DOI Listing |
Publication Analysis
Top Keywords
cyclic benzamidines
8
benzamidines orally
4
orally efficacious
4
efficacious nr2b-selective
4
nr2b-selective nmda
4
nmda receptor
4
receptor antagonists
4
antagonists novel
4
novel series
4
series cyclic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!